Barclays Maintains Overweight on Macrogenics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Overweight rating on Macrogenics (NASDAQ:MGNX) and increased the price target from $12 to $23.
February 29, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Macrogenics and raised the price target from $12 to $23.
The upgrade in the price target by a reputable analyst like Peter Lawson from Barclays indicates a strong confidence in Macrogenics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100